Researchers with the Hawaii Department of Health identified a cluster of Neisseria gonorrhoeae infections that displayed a decreased susceptibility to the double-antibiotic combination used to ...
Postexposure prophylaxis with doxycycline (DoxyPEP) was associated with a substantial decline in the incidence ofsexually transmitted infections (STIs) including Chlamydia trachomatis and Neisseria ...
LAUSANNE, Switzerland & BOSTON--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, is proud to announce the extension of funding from the Combating ...
LAUSANNE, Switzerland & BOSTON--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure ...
FDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against Neisseria gonorrhoeae infection in regions with a high prevalence of gonorrhea ...
Gonorrhoea is resistant to nearly all antibiotics, but one commonly used for urinary tract infections (UTIs) may be able to treat drug-resistant cases. The sexually transmitted infection (STI) is ...
Box 1. Classification of antibiotics in current use, proposed for use or else discontinued for use in the treatment of gonorrhea. I. Antibiotics currently generally recommended for the treatment of ...
Phase 3 findings show oral zoliflodacin to be non-inferior to the combination of ceftriaxone and azithromycin for the treatment of uncomplicated urogenital gonorrhea. Positive study results are a ...
With Debio 1453, Debiopharm aims to provide a potentially valuable addition to the current antibiotic armamentarium, as a new treatment for N. gonorrhoeae infections, especially strains showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results